The chief executive of generic drugmaker Sandoz said a proposal by the CEOs of Novartis and Sanofi to introduce a Europe-wide ...

Good morning, ladies and gentlemen, and welcome to the Sandoz call today. I will now pass on to Craig Marks, Head of Investor Relations, for his opening remarks. Thank you. Welcome to the Sandoz Q1 ...

MEDIA RELEASE Agreement offers rights to commercialize proposed biosimilar of Yervoy®* for treatment of variety of cancer types, targeting net reference medicine sales of USD 2.5 billion[1]Henlius to ...

Both Generics and Biosimilars segments underperformed, though the latter was notably weaker, missing consensus by 9%.

Swiss generics and biosimilars major Sandoz (SIX: SDZ) has signed a global collaboration with Shanghai Henlius Biotech (HKEX: ...

Sandoz has exclusive commercial rights for a biosimilar of ipilimumab in Australia, Canada, Europe, Japan and the United ...

Swiss generics and biosimilars major Sandoz (SIX: SDZ) today presented its net sales update for the first quarter of 2025.

LONDON, April 28 (Reuters) - The chief executive of generic drugmaker Sandoz (SDZ.S), opens new tab said a proposal by the CEOs of Novartis (NOVN.S), opens new tab and Sanofi (SASY.PA), opens new ...

Ad-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Q1 2025 net sales of USD 2,480 million up by 3% in constant currencies (cc); stable in USDup by 5%[1] at a ...

Richard Saynor, Chief Executive Officer of Sandoz, commented: “With Q1 sales in line with our expectations, we have now delivered fourteen consecutive quarters of top-line growth. This ...

It is the powerful combination of delivery and pioneering access for patients that makes us proud to be part of the Sandoz growth journey.” This guidance excludes any impacts of unforeseen events or ...